Scarica l'app Stockscreener
753.93
0.21%
-1.58
Pre-mercato:
750.64
-3.29
-0.44%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché REGN Giù?
Forum
Previsione
Precedente Chiudi:
$755.51
Aprire:
$758.67
Volume 24 ore:
570.54K
Relative Volume:
0.79
Capitalizzazione di mercato:
$79.71B
Reddito:
$14.34B
Utile/perdita netta:
$4.50B
Rapporto P/E:
18.14
EPS:
41.5626
Flusso di cassa netto:
$3.77B
1 W Prestazione:
-2.79%
1M Prestazione:
+1.09%
6M Prestazione:
+30.80%
1 anno Prestazione:
+35.13%
Intervallo 1D:
$739.12
$760.58
Intervallo di 1 settimana:
$737.34
$772.45
Portata 52W:
$476.49
$821.11
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Nome
Regeneron Pharmaceuticals Inc
Settore
Industria
Telefono
(914) 847-7000
Indirizzo
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Compare REGN vs VRTX, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-31 | Ripresa | Piper Sandler | Overweight |
| 2026-03-06 | Iniziato | Barclays | Overweight |
| 2026-01-07 | Aggiornamento | BofA Securities | Underperform → Buy |
| 2025-12-03 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-11-24 | Iniziato | HSBC Securities | Buy |
| 2025-11-24 | Ripresa | Truist | Buy |
| 2025-11-13 | Iniziato | Scotiabank | Sector Perform |
| 2025-08-14 | Iniziato | Rothschild & Co Redburn | Buy |
| 2025-06-30 | Downgrade | Argus | Buy → Hold |
| 2025-05-30 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-05-30 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-05-14 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-04-22 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-02-05 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-01-16 | Downgrade | UBS | Buy → Neutral |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-11-14 | Iniziato | Citigroup | Neutral |
| 2024-09-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-03-12 | Iniziato | Bernstein | Outperform |
| 2024-01-12 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-11-03 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-08-21 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2023-08-21 | Reiterato | Oppenheimer | Perform |
| 2023-06-28 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2023-03-27 | Aggiornamento | SVB Securities | Market Perform → Outperform |
| 2023-03-24 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-03-23 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2023-01-30 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2023-01-20 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-10-26 | Downgrade | Raymond James | Mkt Perform → Underperform |
| 2022-10-17 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-09-09 | Aggiornamento | Jefferies | Underperform → Hold |
| 2022-09-09 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-07-25 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Neutral |
| 2022-06-06 | Iniziato | Jefferies | Underperform |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2022-01-05 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-01-03 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2021-12-15 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2021-12-09 | Ripresa | Wells Fargo | Overweight |
| 2021-12-07 | Ripresa | Cowen | Market Perform |
| 2021-12-06 | Iniziato | Goldman | Buy |
| 2021-11-19 | Ripresa | BMO Capital Markets | Outperform |
| 2021-11-05 | Downgrade | The Benchmark Company | Buy → Hold |
| 2021-06-29 | Iniziato | H.C. Wainwright | Buy |
| 2021-01-25 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2021-01-13 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2021-01-08 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-10-05 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2020-08-20 | Downgrade | The Benchmark Company | Buy → Hold |
| 2020-07-09 | Aggiornamento | SunTrust | Hold → Buy |
| 2020-05-26 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2020-04-28 | Downgrade | Citigroup | Buy → Neutral |
| 2020-04-17 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2020-04-08 | Iniziato | The Benchmark Company | Hold |
| 2020-03-31 | Iniziato | Wolfe Research | Peer Perform |
| 2020-02-27 | Iniziato | Barclays | Overweight |
| 2020-02-26 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2020-02-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-02-25 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-02-11 | Aggiornamento | Argus | Hold → Buy |
| 2019-12-24 | Iniziato | Raymond James | Mkt Perform |
| 2019-12-16 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-12-13 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-11-12 | Iniziato | SunTrust | Hold |
| 2019-11-07 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-09-23 | Aggiornamento | Guggenheim | Neutral → Buy |
Mostra tutto
Regeneron Pharmaceuticals Inc Borsa (REGN) Ultime notizie
A Look At Regeneron Pharmaceuticals (REGN) Valuation After New Telix Radiopharmaceutical Collaboration - simplywall.st
Generalized Myasthenia Gravis Market on the Brink of Change: 8 Promising Late-Stage Drugs Signal a New Treatment Era | DelveInsight - GlobeNewswire Inc.
Regeneron Pharmaceuticals Inc (REGN) Stock Price, Trades & News - GuruFocus
Telix Pharmaceuticals to collaborate with Regeneron on cancer therapies - Indianapolis Business Journal
Inside Biotech: Telix rally meets reality check as $600m raise tempers Regeneron-driven surge - Proactive Investors
Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Illumine Investment Management, LLC's Regeneron Pharmaceuticals Inc(REGN) Holding History - GuruFocus
Regeneron Boosts Cancer Pipeline Through Telix Collaboration - Yahoo Finance
A $2.1 Billion Radiopharmaceutical Collaboration, Explained - PharmTech.com
Third View Private Wealth Boosts Regeneron Pharmaceuticals Stake - National Today
Earnings Preview: What to Expect From Regeneron Pharmaceuticals' Report - Yahoo Finance
Third View Private Wealth LLC Acquires Shares of 7,149 Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Why Telix Pharmaceuticals (ASX:TLX) Is Up 13.8% After Regeneron Radiopharma Alliance Announcement And What’s Next - Yahoo Finance
Novo teams with OpenAI; Ideaya gets muted response to eye drug data - Yahoo Finance
Is It Too Late To Consider Regeneron (REGN) After Its 31% One‑Year Rally? - simplywall.st
Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria - WebWire
Regeneron (REGN) Partners with Telix Pharmaceuticals for Innovat - GuruFocus
Regeneron Pharmaceuticals Inc stock (US7739031091): Is Eylea dominance still the real growth engine? - AD HOC NEWS
Telix And Regeneron Pharmaceuticals Partner To Advance Next Generation Radiopharmaceutical Therapies - BioPharma APAC
Regeneron Pharmaceuticals (REGN) Partners with Telix for Radioph - GuruFocus
Regeneron and Telix reveal radiopharm collab - The Pharma Letter
Regeneron enters radiopharma space via Telix deal - BioWorld News
Regeneron Enters $2.1 Billion Radiopharma Collaboration with Telix Pharmaceuticals - Pharmaceutical Executive
Regeneron, Telix Enter Strategic Radiopharma Collaboration - Contract Pharma
SNY & REGN's Dupixent Gets EU Approval for Pediatric Use in Urticaria - Yahoo Finance Singapore
The Science of Scale: An In-Depth Look at Regeneron Pharmaceuticals (REGN) in 2026 - FinancialContent
Regeneron enters radiopharma ring with up to $4.3B Telix alliance - BioSpace
Telix Pharma Gains As Regeneron Tie-Up Targets Solid Tumor ProgramsRegeneron Pharmaceuticals (NASDAQ:R - Benzinga
Regeneron, Sanofi Get Expanded Europe OK for Dupixent in Younger Children With CSU - National Today
Regeneron (REGN) Partners with Telix Pharmaceuticals - GuruFocus
H.C. Wainwright reiterates Telix stock rating on Regeneron deal - Investing.com
Regeneron, Telix partner on radiopharmaceutical cancer therapies By Investing.com - Investing.com Canada
Telix and Regeneron sign $4.3bn deal to co-develop radiopharmaceutical therapies - Yahoo Finance
Regeneron, Telix partner on radiopharmaceutical cancer therapies - Investing.com
Regeneron and Telix Announce Strategic Radiopharma Collaboration - The Manila Times
Regeneron taps Telix in $40M push for next-generation cancer drugs - Stock Titan
Sumitomo Mitsui Trust Group Inc. Cuts Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Burney Co. Acquires New Shares in Regeneron Pharmaceuticals, Inc. $REGN - National Today
Dupixent® (dupilumab) Approved in the EU as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria (CSU) - National Today
Sanofi (SNY) and Regeneron (REGN) Gain EU Approval for Dupixent in Young Children - GuruFocus
Sanofi, Regeneron’s Dupixent approved in EU for young children with chronic urticaria (SNY:NASDAQ) - Seeking Alpha
Dupixent Approved in EU for Treating Children with CSU - Intellectia AI
Regeneron and Sanofi Announce European Commission Approval of Dupixent for Chronic Spontaneous Urticaria in Children Aged 2 to 11 Years - Quiver Quantitative
Press Release: Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria - The Manila Times
Australia's Telix Pharma announces strategic radiopharma collaboration worth $535 M with Regeneron - BioSpectrum Asia
Regeneron Pharmaceuticals, Inc. (REGN) Shares Plunge Despite Positive Phase 3 Itepekimab Results - MSN
Telix Pharmaceuticals announces US$40m Regeneron radiopharma deal - The Motley Fool Australia
Telix and Regeneron Announce Strategic Radiopharma Collaboration - PR Newswire
Jim Cramer on Regeneron (REGN): “I Think The Stock’s Breaking Out Here” - Insider Monkey
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit - GuruFocus
Robeco Institutional Asset Management Boosts Regeneron Pharmaceuticals Stake - National Today
Regeneron Pharmaceuticals Inc Azioni (REGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.51%
0.58%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):